Abstract
Fatty acid binding protein (FABP4) inhibitors are of synthetic and therapeutic interest and ongoing clinical studies indicate that they may be a promise for the treatment of cancer, as well as other diseases. As part of a broader research effort to develop more effective FABP4 inhibitors, we sought to identify new structures through a two-step computing assisted molecular design based on the established scaffold of a co-crystallized ligand. Novel and potent FABP4 inhibitors have been developed using this approach and herein we report the synthesis, biological evaluation and molecular docking of the 4-amino and 4-ureido pyridazinone-based series.
Original language | English |
---|---|
Article number | 1335 |
Journal | Pharmaceuticals |
Volume | 15 |
Issue number | 11 |
Early online date | 28 Oct 2022 |
DOIs | |
Publication status | Published - 30 Nov 2022 |
Bibliographical note
Funding Information:This research has received funding for a scholarship to R.R.d.O.S from the Coordination for the Improvement of Higher Education Personnel—Brazil (CAPES-PRINT, funding number 88887.570120/2020-00).
Keywords
- computing assisted molecular design
- FABP4
- FABP4 inhibitors
- FABP4is
- fatty acid binding protein
- pyridazinone
ASJC Scopus subject areas
- Molecular Medicine
- Pharmaceutical Science
- Drug Discovery
Fingerprint
Dive into the research topics of 'Ligand Growing Experiments Suggested 4-amino and 4-ureido pyridazin-3(2H)-one as Novel Scaffold for FABP4 Inhibition'. Together they form a unique fingerprint.Equipment
-
Avance 300 MHz Nuclear Magnetic Resonance (NMR) Spectrometer (1South)
Material and Chemical Characterisation (MC2)Facility/equipment: Equipment